@Article{Wiland2011,
journal="Reumatologia/Rheumatology",
issn="0034-6233",
volume="49",
number="4",
year="2011",
title="Certolizumab pegol in the treatment of rheumatoid arthritis",
abstract="Recently a new drug inhibiting TNF, certolizumab pegol, has been produced and tested in numerous laboratory and clinical trials. Owing to pegylation (addition of polyethylene glycol to the Fab fragment of TNF neutralizing antibody) this molecule shows different properties in comparison to other TNF neutralizing drugs. The present paper describes similarities as well as differences in mechanisms of action, pharmacokinetics, metabolism, clinical efficacy, influence of radiological progression and safety of certolizumab in comparison to other biological drugs inhibiting TNF used for the treatment of patients with rheumatoid arthritis (Table I-III). The results of clinical trials revealed relatively fast response to certolizumab (Table II, Figure 1). In addition, it was possible to predict, with rather high probability, the long term efficacy of this drug, which may be important for pharmacoeconomics of the treatment.",
author="Wiland, Piotr
and Świerkot, Jerzy
and Maśliński, Włodzimierz",
pages="253--263",
url="https://www.termedia.pl/Certolizumab-pegol-in-the-treatment-of-rheumatoid-arthritis-,18,17172,1,1.html"
}